SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE:A) today announced that the Wellcome Trust Case Control Consortium (WTCCC) will standardize the world’s largest human genomic copy number variation (CNV) study on Agilent microarrays. The study is designed to determine genetic causes of certain widespread diseases. The samples will be processed by Oxford Gene Technology (OGT), an Agilent microarray Certified Service Provider located in Oxford, UK. Financial terms were not disclosed.
